ORIC-613 (Oric Pharmaceuticals)

N/A

Report date: 2024/01/16 09:04:18
NME

Base Information

Drug NameORIC-613 (Oric Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPolo like kinase 4 inhibitors
TargetsPolo like kinase 4
Therapy Area/IndicationsBreast NeoplasmsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOric Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesOric Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsBreast NeoplasmsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A